LiDCO Group plc (AIM: LID), the cardiovascular monitoring company, is very pleased to announce the purchase of five LiDCOplus Hemodynamic Monitors by Wilford Hall Medical Center at Lackland Air Force Base in San Antonio, Texas, following the successful trial of the monitors at this major US Air Force hospital facility. These purchases, at a value of $85,000, follow on from the company's successful sale of 31 LiDCOplus Hemodynamic Monitors to the US Army toward the end of 2005.

Wilford Hall Medical Center, the US Air Force's largest medical facility, provides complete medical care to military healthcare beneficiaries in the South Central United States as well as specialised care to patients referred from all over the world. The hospital has more than 16,000 inpatient admissions each year.

Wilford Hall has previously purchased a LiDCOplus monitor which is being used in their research laboratory to provide information to better help critically ill ECMO (Extra Corporeal Membrane Oxygenation) patients.

John Barry, Director of Sales and Marketing for LiDCO Group plc, stated: “We are delighted that Wilford Hall Medical Center has chosen our minimally invasive LiDCOplus monitoring technology. This is particularly gratifying in that it follows so quickly on the heels of the recent US Army order. We look forward to working with the clinicians at Wilford Hall to help implement our product in a manner that provides maximum benefit to them and their patients”.

Notes to Editors

About LiDCO Plc

LiDCO is a UK-based AIM-traded developer, manufacturer and leading supplier of minimally invasive, computer-based hemodynamic monitoring equipment and disposables used primarily for the management of critical care and cardiovascular risk hospital patients. Use of LiDCO's technology has been shown to significantly reduce the complications (particularly infections) and costs associated with major surgery. The technology was invented in the Department of Applied Physiology based at St Thomas' Hospital, London where the Company maintains a research base.

The Company’s manufacturing facility is in Hoxton, London and its current products are:

• LiDCOplus and PulseCO monitors: computer-based platforms for displaying a range of real-time, continuous hemodynamic parameters including cardiac output, oxygen delivery and fluid volume;

• LiDCO disposables: used in conjunction with the LiDCOplus Monitor to accurately determine cardiac output in a minimally-invasive manner.

Distribution Network:

The Company has now achieved registration of its products in 13 markets in Europe, the USA, Brazil and Japan. It sells direct to the NHS in the UK, and through a worldwide network of specialty critical care distributors.

Background to a recently published clinical trial:

A major trial at St George's Hospital, London, using LiDCO's minimally invasive monitoring technology, revealed the following:

1. Savings in the cost of treating patients amounting to an average of 12 days less spent in the hospital saving approximately £4,800 per patient. Extrapolated nationally, this would equate to a saving of £500 million per annum for the NHS

2. The savings in hospital days were associated with a significant reduction in medical complications (particularly infections - which were halved) and improved tissue oxygen levels following surgery were also observed through the use of LiDCO's minimally invasive technology.